Renadirsen

N/A

Report date: 2023/05/11 13:30:52
NME

Base Information

Drug NameRenadirsen
Drug Alias NameDS-5141DS-5141b
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionDystrophin expression stimulantsDystrophin pre-mRNA modulators
TargetsDystrophin pre-mRNA
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDaiichi Sankyo Co Ltd
Active IndicationsN/A
Inactive IndicationsMuscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A